Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug
response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 development for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the 3rd line treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of 2nd line metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 development for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 development for metastatic breast cancer and/or glioblastoma multiforme. The company was founded in 2004 and is headquartered in Cambridge, Massachusetts. The company trades on NGM exchange. The company headquarter is located in Cambridge ,United States.
| Ticker | ALLR |
| Long Name | Allarity Therapeutics, Inc. |
| Short Name | Allarity Therapeutics, Inc. |